HCW Biologics — Third Quarter 2026 Earnings Summary
HCW Biologics reported a net loss of $3.2 million for the three months ended September 30, 2026, and $5.0 million for the nine-month period, driven by research and development expenses of $1.2 million and $3.7 million respectively. The company secured $8.6 million in equity financing and $3.0 million in debt financing during the first nine months of 2026 to support its Phase 1 clinical trial for HCW9302 in alopecia areata and preclinical programs. Clinical progress includes the activation of an additional site for the HCW9302 study and FDA guidance to file an IND application for the solid tumor candidate HCW11-018b in the first half of 2027. Despite these advancements, the company disclosed substantial doubt regarding its ability to continue as a going concern for the next 12 months without additional funding.
- Company
- HCW BIOLOGICS INC
- Sector
- Healthcare
- Industry
- Biotechnology